Modeling subpopulations with the $MIXTURE subroutine in NONMEM: Finding the individual probability of belonging to a subpopulation for the use in model analysis and improved decision making

AAPS Journal

Volumn 11, Issue 1, 2009, Pages 148-154

  Carlsson, Kristin C ^a,b   Savi, Radojka M ^a   Hooker, Andrew C ^a   Karlsson, Mats O ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b NOVO NORDISK A S   (Denmark)

Author keywords

Mixture; NONMEM; Pharmacometrics; Population modeling; Subpopulation

Indexed keywords

CLOMETHIAZOLE; PLACEBO; PREGABALIN;

ACCURACY; ADD ON THERAPY; ANALYTICAL ERROR; ARTICLE; CONTROLLED STUDY; DRUG RESEARCH; DRUG RESPONSE; EPILEPSY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; POPULATION MODEL; PROBABILITY; SEDATION; SIDE EFFECT; SIMULATION;

EID: 65549123673     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-009-9093-4     Document Type: Article

References (11)

1. L. Aarons. Software for population pharmacokinetics and pharmacodynamics. Clin. Pharmacokinet. 36:255-264 (1999).
2. S. Sadray, E. N. Jonsson, and M. O. Karlsson. Likelihood-based diagnostics for influential individuals in non-linear mixed effects model selection. Pharm Res. 16:1260-1265 (1999).
3. P. H. Zingmark, M. Ekblom T. Odergren et al. Population pharmacokinetics of clomethiazole and its effect on the natural course of sedation in acute stroke patients. Br. J. Clin. Pharmacol. 56:173-183 (2003).
4. R. Miller, B. Frame B. Corrigan et al. Exposure-response analysis of pregabalin add-on treatment of patients with refractory partial seizures. Clin. Pharmacol. Ther. 73:491-505 (2003).
5. T. Tanigawa, R. Heinig, Y. Kuroki, and S. Higuchi. Evaluation of interethnic differences in repinotan pharmacokinetics by using population approach. Drug Metab Pharmacokinet. 21:61-69 (2006).
6. R. Hussein, B. G. Charles, R. G. Morris, and R. L. Rasiah. Population pharmacokinetics of perhexiline from very sparse, routine monitoring data. Ther. Drug Monit. 23:636-643 (2001).
7. B. Facca, B. Frame, and S. Triesenberg. Population pharmacokinetics of ceftizoxime administered by continuous infusion in clinically ill adult patients. Antimicrob. Agents Chemother. 42:1783-1787 (1998).
8. V. Piotrovsky, A. Van Peer, N. Van Osselaer, M. Armstrong, and J. Aerssens. Galantamine population pharmacokinetics in patients with Alzheimer's disease: Modeling and simulations. J. Clin. Pharmacol. 43:514-523 (2003).
9. N. Frey, C. Laveille, M. Paraire, M. Francillard, N. H. Holford, and R. Jochemsen. Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation. Br. J. Clin. Pharmacol. 55:147-157 (2003).
10. K. G. Kowalski, L. McFadyen, M. M. Hutmacher, B. Frame, and R. Miller. A two-part mixture model for longitudinal adverse event severity data. J. Pharmacokinet. Pharmacodyn. 30:315-336 (2003).
11. M. E. Spilker, K. Y. Seng A. A. Yao et al. Mixture model approach to tumor classification based on pharmacokinetic measures of tumor permeability. J. Magn. Reson. Imaging. 22:549-558 (2005).